iShares Russell 1000 Growth ETF

IWF

Market cap $132B

You buy the iShares Russell 1000 Growth ETF (NYSEARCA:IWF | IWF Price Prediction) expecting broad growth exposure.

Every bull market since 2016 has been a mega cap story. The S&P 500's gains over the past decade have been driven by a handful of growth giants whose weight in the index keeps expanding.

The Middle East crisis led to a broad selloff in Russell equity segments in March halting the year-long rally. 12M forward P/Es derated broadly but more so for Russell 1000, Top 200 and the large- and small-cap Growth indices partly due to their heavy Tech exposure and valuation expansion over the last three years.

The rebound in the S&P 500 and expectations of resilient earnings signal a risk-on shift. Growth ETFs may be poised for a rebound.

Looking for broad exposure to the Large Cap Growth segment of the US equity market? You should consider the iShares Russell 1000 Growth ETF (IWF), a passively managed exchange traded fund launched on May 22, 2000.

Growth investing has had a choppy start to 2026. The major growth benchmarks are down in the low single digits year-to-date, and some of the biggest names in tech have pulled back meaningfully from their late-2025 highs.

Most large cap growth ETFs hand you a market-cap-weighted slice of the same mega-cap names and call it a day.

I'm always on the lookout for the best-quality exchange traded funds (ETFs) in the market, across a range of sectors.

Looking for broad exposure to the Large Cap Growth segment of the US equity market? You should consider the iShares Russell 1000 Growth ETF (IWF), a passively managed exchange traded fund launched on May 22, 2000.

Eli Lilly's stock price has underperformed this year, much of it on the back of drug pricing concerns, potential tariff impacts and, perhaps, less enthusiasm for GLP-1 drugs. The primary drag for the quarter was Oracle, accounting for almost all of the Portfolio's relative underperformance in Q4, completely reversing its performance from the prior quarter and giving back all of the gains experienced in Q3. Polen Capital initiated a 2.25% position in Intuitive Surgical who maintain a de facto monopoly in soft tissue robotic surgery globally.